Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA2 | P16389 | 2/20 | 0.89 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.89 |
| ▸ | KCNA1 | Q09470 | 2/20 | 0.89 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9678430 | 0.84 | KCNA3 (0.80) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL3189671 | 0.84 | KCNA3 (1.00) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL3607797 | 0.83 | KCNA2 (0.69) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL13920855 | 0.82 | KCNA3 (1.00) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL10998626 | 0.81 | KCNA2 (0.61) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL13920858 | 0.80 | KCNA3 (0.84) | KCNA3 | |
| SCHEMBL10884152 | 0.79 | KCNA3 (0.80) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL12133188 | 0.78 | KCNA3 (0.83) | KCNA2KCNA5KCNA1KCNA4KCNH2 | |
| SCHEMBL7300636 | 0.78 | KCNA3 (0.71) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL10924160 | 0.77 | KCNA2 (0.70) | KCNA2KCNA5KCNA1KCNA4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-8063093-B2 | Derivatives of 5-(halo)alkanoyl-6-hydroxy- benozofuran, benzothiophene, or indole; autoimmune diseases; systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis and psoriasis, transplant rejection; antiproliferative, anticarcinogenic, antidiabetic, antiinflammatory and antiulcer agents | HARVEY ANDREW J (AU) | 2011-11-22 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | HARVEY ANDREW J | 2008-09-11 | — | — | US | disclosed |
| WO-2008040058-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040057-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| WO-2006096911-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | HARVEY ANDREW J (AU) | 2006-09-21 | — | — | WO | disclosed |
| EP-0303920-B1 | BENZOFURAN DERIVATIVES AND THERAPEUTIC AGENTS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1992-03-18 | — | — | EP | disclosed |
| US-5039701-A | Calcium antagonists for treatment of heart disease, vasospasms, hypertension | BASF AKTIENGESELLSCHAFT (DE) | 1991-08-13 | — | — | US | disclosed |
| EP-0303920-A1 | Benzofuran derivatives and therapeutic agents containing them | BASF Aktiengesellschaft (DE) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | KCNA2 31/4885KCNA5 21/4885KCNA1 14/4885 |
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | KCNAB1, KCNB1, KCNMB1 | KCNA2 17/4885KCNA5 14/4885KCNA1 7/4885 |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNK3, KCNA3, KCND3 | KCNA2 34/4885KCNA5 32/4885KCNA1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.